Fixed-Ratio Combination Therapy in T2DM

Slides:



Advertisements
Similar presentations
Abstract Objective: Intensive insulin management (IIM) improves glycemic control, and lowers the risks of long-term microvascular complications. In children,
Advertisements

What's New in Basal Insulin for Diabetes
Case-Based Examination of Treatment Options in Type 2 Diabetes Management.
Recommendation In people with clinical cardiovascular disease in whom glycemic targets are not met, a SGLT2 inhibitor with demonstrated cardiovascular.
Short-, Intermediate-, Long-Acting Insulins
Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.
Applying Data to Practice
Heart Rate, HF Admissions, and Readmissions
New Patient-Friendly Options for Managing Insulin Dosing
Glaucoma Progression.
The Next Generation of Basal Insulins
Modern Strategies for Basal Insulin Use in T2D
Insulin Innovation.
Insulin/GLP-1 Agonist Combinations
Program Goals. Consulting the Experts: Prandial Insulin or a GLP-1 Receptor Agonist as Add-On to Basal Insulin.
Insulin Intensification Strategies in Later-Stage Type 2 Diabetes Mellitus.
Agenda. Insulin Intensification Strategies: An Expert Perspective from Asia-Pacific.
SGLT2 Inhibitors in Phase 3 Trials
Novel Concentrated Insulins: What Benefits and for Which Patients?
How to Achieve Aggressive BP Goals in Difficult-to-Treat Patients
Updates Abound.
Working as a Team for Improved Patient Outcomes in Type 2 Diabetes
Examining CV Effects of Basal Insulin Therapy
What Do Primary Care Physicians Need to Know About Insulin/GLP-1 RA Fixed-Ratio Combinations?
Innovative Insulin Combinations: A New strategy for the Person With T2DM.
Program Goals. What Will the Emerging Basal Insulin Products Mean for My Diabetes Practice?
Blood pressure control: dependence on adherence
Emerging Basal Insulins for Diabetes
Insights into Insulin Treatment Challenges: Real-World Evidence and Clinical Trial Data.
GLP-1 Receptor Agonists: How Early Is Appropriate?
Need to Know! Screening and Diagnosis of Kidney Disease in Diabetes
Clinical Updates in RA: New Developments and Insights From Washington
Introduction. A Reality Check on BP Goals and Optimizing Patient Adherence to Treatment.
Novel Insulin Combinations: What Does the Primary Care Physician Need to Know?
Integrated Diabetes Care: How Can We Make the Best Use of New Technology?
Novel Basal Insulin Formulations in the Modern Era of T2D Management
Insulin/GLP-1 Agonist Combinations
Insulin Use in Primary Care: Practice Challenges
Insulin Innovation.
Program Goals Overview Glatiramer Acetate 3 Times a Week.
Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes Patients.
New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.
Translating the Latest and Greatest Advances in PAH Into Clinical Practice.
Simplifying Insulin Delivery for Better Patient Outcomes in T2D
Novel Approaches to T1D Management
Clinicians' Corner in Dyslipidemia
T2DM Management.
Better Diabetes Control With Novel Basal Insulins
Novel Insulin/GLP-1 Combinations: Of Interest to the Primary Care Physician?
What's New in Therapeutic Options for Moderate to Severe RA?
Program. Basal Insulin in the Modern Era The CDE's Role in Improving Utilization and Outcomes.
Optimizing Insulin Therapy in Primary Care: Basal Plus Incretin Combinations.
CV Risk Reduction with Diabetes Drugs -- Should Cardiologists or Diabetologists Take the Lead?
Oral Combination Therapy for T2D
Panelists. Cardiovascular Risk Modulation in Diabetes: Emerging Pathways and Insights.
Dual SGLT1/SGLT2 Inhibition in T1D
Insulin in Diabetes Management: Effective Patient Selection Is Key
COMBINATIONS AND COFORMULATIONS: THE FUTURE OF INSULIN THERAPY?
Add-On Therapy to Insulin in T1DM Management
Incorporating Prostacyclins Into Practice
Improving Effective Basal Insulin Use in Clinical Practice
Respondents’ perceptions on (A) the potential of IDegLira compared with basal-bolus therapy to improve patient motivation to reach their target blood glucose.
Renal Function and Myeloma Therapeutics
Getting PPG Under Control
Emerging Combination Injectable Therapy A New Era in Diabetes Care
Risk Stratification of Patients With Type 2 Diabetes: An Interpretation of the Latest Treatment Guidelines.
Emerging Basal Insulins for Diabetes
Fresh perspectives ON BASAL Insulins in diabetes care
In the Know.
The Challenge of Insulin Titration
Presentation transcript:

Fixed-Ratio Combination Therapy in T2DM

Program Overview

Consequences of Delaying Intensification of Therapy in T2DM

Therapeutic Inertia

Likelihood of Achieving Glycemic Control With Basal Insulin

Healthcare System Barriers to Advancing Therapy

Intensification of Insulin Therapy With FRCs

Benefits of Basal Insulin/GLP-1 RA FRCs

Practical Benefits of Basal Insulin/GLP-1 RA FRCs

Basal Insulin/GLP-1 RA FRC Agents

Reduction in Risk for Side Effects

Impact of T2DM Duration on Response to IGlarLixi v Glargine

Mean Daily Dose of Basal Insulin Significantly Lower With FRC Therapy

The Importance of Individualizing Therapy

IDegLira vs Basal-Bolus Insulin

FRC vs Prandial Insulin

Carbohydrate Counting

Use of FRCs in Clinical Practice

Use of FRCs in Clinical Practice (cont)

Patients Who Could Benefit From FRCs

Practical Considerations for Using FRCs

Using a Basal Insulin/GLP-1 RA FRC - IGlarLixi

Using a Basal Insulin/GLP-1 RA FRC - IDegLira

Summary

Abbreviations

Abbreviations (cont)

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.